8-K: Urogen Pharma Secures FDA Approval for ZUSDURI in Bladder Cancer Treatment

Urogen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ZUSDURI (mitomycin), formerly UGN-102, for the treatment of recurrent low-grade intermediate risk non-muscle invasive bladder cancer.

Summary

• On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved ZUSDURI (mitomycin), previously known as UGN-102.
• ZUSDURI is a sustained-release gel formulation of mitomycin indicated for the treatment of adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
• The approval is based on data from the pivotal Phase 3 ENVISION trial, where 78% of patients achieved a complete response at three months.
• Furthermore, 79% of those responders maintained a complete response at 12 months after the three-month visit.
• ZUSDURI is anticipated to be commercially available in the United States around July 1, 2025.
• As a post-marketing commitment, Urogen Pharma agreed with the FDA to complete the ongoing ENVISION trial to further characterize ZUSDURI's clinical benefit.
• The company also committed to providing interim trial reports and annual updates on duration of response data for all patients with ongoing complete responses as of the October 2024 data cutoff date (Month 21).

Sentiment

Score: 9

Explanation: The sentiment is overwhelmingly positive due to the FDA approval of a key product, ZUSDURI, which is a significant commercial and clinical milestone. The strong efficacy data from the pivotal trial further enhances this positive outlook, despite the mention of adverse reactions which are common in drug approvals.

Positives

• FDA approval of ZUSDURI provides a new treatment option for recurrent LG-IR-NMIBC, addressing an unmet medical need.
• The pivotal Phase 3 ENVISION trial demonstrated strong efficacy, with 78% of patients achieving complete response at three months.
• A high percentage (79%) of responders maintained complete response at 12 months, indicating durable efficacy.
• Expected commercial availability by July 1, 2025, suggests a rapid transition to market and potential revenue generation.

Negatives

• Serious adverse reactions occurred in 12% of patients who received ZUSDURI, including urinary retention (0.8%) and urethral stenosis (0.4%).
• Common adverse reactions (>=10%) included increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Risks

• Challenges associated with commercially launching a new product.
• New data from spontaneous adverse event reports or the ongoing ENVISION trial may lead to changes in the product label.
• Potential for new data to adversely affect sales or even result in the withdrawal of ZUSDURI from the market.
• Other risks and uncertainties are described in the Risk Factors section of the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 12, 2025.

Future Outlook

Urogen Pharma expects ZUSDURI to be available in the United States around July 1, 2025. The company has committed to completing the ongoing ENVISION trial and providing the FDA with interim trial reports and annual updates on duration of response data for all patients with ongoing complete responses, continuing until specific endpoints are met or 63 months after first instillation.

Management Comments

• The Current Report on Form 8-K was signed by Chris Degnan, Chief Financial Officer of UROGEN PHARMA LTD., on June 13, 2025.

Industry Context

The FDA approval of ZUSDURI represents a significant advancement in the treatment landscape for recurrent low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Bladder cancer is a common malignancy, and NMIBC accounts for a substantial portion of cases. This approval introduces a novel sustained-release gel formulation, potentially offering a more convenient and effective treatment option compared to existing therapies, which could improve patient outcomes and market share in the urological oncology sector.

Stakeholder Impact

• **Shareholders:** Highly positive impact due to the FDA approval, which is expected to drive future revenue and potentially increase share price.
• **Patients:** Positive impact as ZUSDURI offers a new, potentially more effective and convenient treatment option for recurrent LG-IR-NMIBC.
• **Healthcare Providers:** Provides a new therapeutic tool for managing bladder cancer, potentially improving patient care.
• **Employees:** Positive impact through increased job security and potential for company growth and expansion.

Next Steps

• Commercial launch of ZUSDURI in the United States, expected around July 1, 2025.
• Completion of the ongoing ENVISION trial to further characterize the clinical benefit of ZUSDURI.
• Provision of interim trial reports and annual updates to the FDA regarding duration of response data for patients with ongoing complete responses.

Key Dates

Recommendation

Keywords

Urogen Pharma, ZUSDURI, UGN-102, FDA approval, bladder cancer, LG-IR-NMIBC, non-muscle invasive bladder cancer, mitomycin, oncology, pharmaceutical, clinical trial, ENVISION trial, drug approval